CRISPR Therapeutics 将来の成長
Future 基準チェック /26
CRISPR Therapeutics利益と収益がそれぞれ年間63%と64.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-46.1% 62.6%なると予測されています。
主要情報
63.0%
収益成長率
62.64%
EPS成長率
| Biotechs 収益成長 | 25.5% |
| 収益成長率 | 64.1% |
| 将来の株主資本利益率 | -46.13% |
| アナリストカバレッジ | Good |
| 最終更新日 | 13 May 2026 |
今後の成長に関する最新情報
Recent updates
Seeking Alpha • May 06
Crispr Therapeutics Q1 Earnings: Casgevy Growth, H2 In-Vivo Catalysts Make Buy Case
Summary Crispr Therapeutics AG is positioned as a long-term buy-and-hold, underpinned by its pioneering gene editing platform and commercial-stage asset Casgevy. Casgevy revenues fell sequentially, but >500 patients have initiated treatment, supporting a multibillion-dollar opportunity with a large, underpenetrated addressable market. CRSP's pipeline offers near-term catalysts in autoimmune and in-vivo gene editing, with several Phase 1 updates expected later this year. Despite high quarterly cash burn, CRSP's $2bn+ liquidity and consistent execution justify its $5bn market cap and continued optimism. Read the full article on Seeking Alpha分析記事 • Mar 27
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Mar 14
CRISPR Therapeutics: An Uninspiring Start For Casgevy
Summary CRISPR Therapeutics' stock is down 19% since December, with a slow Casgevy launch and significant R&D investments, yet strong cash reserves provide a safety net. Q4 earnings show no revenue from Casgevy yet, but $35M in collaboration revenue from Vertex and a net loss of $37.311M. Despite pioneering technology, CRISPR faces slow gene therapy adoption and stiff competition in CAR-T therapies, with no exciting pipeline developments. CRISPR remains a cautious "Hold" within a barbell portfolio, pending momentum from Casgevy's launch and clinical trial success outside rare diseases. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Summary Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable securities. Casgevy, a gene-edited therapy for Sickle Cell Disease and beta thalassemia, shows promising clinical results but has yet to generate significant revenue due to lengthy treatment processes. The company is focused on easing pre-conditioning regimes and developing allogeneic and in-vivo therapies, which could exponentially increase the addressable market and drive future revenue growth. With major data readouts expected in 2025 and potential Casgevy revenues, CRSP stock remains a compelling investment despite current share price stasis. Read the full article on Seeking AlphaSeeking Alpha • Jan 16
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
Summary CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic partnership with Vertex Pharmaceuticals has provided stability and resources, leading to the first FDA-approved CRISPR-based gene editing treatment, Casgevy. Editas' discontinuation of its SCD and TDT program and significant layoffs highlight its precarious position compared to CRISPR's better financial health and strategic advantages. CRISPR's current valuation is attractive, with $1.9 billion in cash and expected revenue from Casgevy, making it a speculative but compelling buy. Read the full article on Seeking Alpha分析記事 • Dec 31
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Not Quite Adding Up
CRISPR Therapeutics AG's ( NASDAQ:CRSP ) price-to-sales (or "P/S") ratio of 16.3x might make it look like a strong sell...Seeking Alpha • Dec 29
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025
Summary Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 2024. Despite a slow roll-out, Casgevy's increasing patient demand, reimbursement agreements, and positive long-term efficacy data support a bright revenue outlook and potential profitability by 2028. Crispr's robust pipeline, including CTX310 and CTX320 for cardiovascular diseases, holds blockbuster potential, with top-line results expected in 2025, enhancing long-term growth prospects. With $1.9 billion in cash, Crispr has financial stability for at least 3.6 years, supporting ongoing development without needing to raise capital, making it a "buy" for high-risk tolerant investors. Read the full article on Seeking Alpha分析記事 • Dec 03
Here's Why We're Not Too Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Nov 11
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Summary CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals. With nearly $2bn in cash and a promising pipeline, CRISPR Therapeutics remains a compelling long-term investment - I'm anticipating significant developments by 2025. Read the full article on Seeking Alpha分析記事 • Nov 07
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results
It's been a good week for CRISPR Therapeutics AG ( NASDAQ:CRSP ) shareholders, because the company has just released...Seeking Alpha • Oct 28
Crispr Therapeutics: Poised For A Major Turnaround
Summary Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharmaceuticals has provided significant financial support, experienced leadership, and validation, positioning Crispr for long-term success in the gene-editing space. Crispr's shares are currently undervalued, offering a strong buy opportunity below $50, with incoming revenue from Casgevy and a promising drug pipeline. Despite competition, Crispr's first-mover advantage, strategic partnerships, and robust pipeline create a durable moat, making it a compelling investment in the biotech sector. Read the full article on Seeking Alpha分析記事 • Oct 02
CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
With a price-to-sales (or "P/S") ratio of 20x CRISPR Therapeutics AG ( NASDAQ:CRSP ) may be sending very bearish...Seeking Alpha • Sep 13
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Summary Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade. CRSP remains highly shorted, with 20% of shares outstanding sold short. Considering Crispr's secular growth in the long term, perhaps short sellers are betting on near-term negative catalysts. Vertex is exploring an alternative to using Busulfan, which is used to clear out existing patient stem cells; finding a less toxic agent could increase Casgevy's patient population to 150k. Read the full article on Seeking Alpha分析記事 • Sep 04
Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Aug 14
Crispr's Casgevy Launch: Promising Start, Uncertain Future
Summary CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns. CRISPR's partnership with Vertex Pharmaceuticals mitigates some operational risks associated with gene therapy. Given the uncertainties, CRISPR Therapeutics stock remains a "hold" until clearer commercial success is evident. Read the full article on Seeking Alpha分析記事 • Aug 09
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Key Insights Using the 2 Stage Free Cash Flow to Equity, CRISPR Therapeutics fair value estimate is US$46.96 Current...Seeking Alpha • Aug 07
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Summary Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey involves a lengthy process with no revenue recognition until the end, but the therapy has shown high effectiveness in clinical studies. Crispr Therapeutics and Vertex are working on reducing preconditioning burden for Casgevy patients and exploring the potential of in vivo therapies for the future. Crispr made a net loss of $126.4m in Q2, but retains ~$1.7bn of cash, and its pipeline contains assets potentially approvable near term, plus two in-vivo programs offering breakthrough treatments. In my view, Crispr Therapeutics is remains a highly attractive company to invest in with a clear path to >41bn in annual revenues. Read the full article on Seeking AlphaSeeking Alpha • Jul 13
Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Summary CRSP has achieved the highly coveted regulatory approval for its gene editing technology as therapy for Severe Sickle Cell Disease and Thalassemia. However, with revenue recognition only likely from Q4'24 or Q1'25 onwards, readers may want to temper their near-term expectations. At the same time, CRSP does not own the patent of its gene editing technology, with a patent battle still occurring between the two groups of inventors. As the stock continues to trade sideways since November 2021, we believe that its intermediate-term investment thesis is likely tied to its swing trade potential. CRSP is likely to remain volatile as well, attributed to the elevated short interest and intense insider selling, with it only suitable for investors with higher risk tolerance. Read the full article on Seeking AlphaSeeking Alpha • Jul 07
Crispr Therapeutics: Beaten Down But Not Broken
Summary CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program. CRSP aims to expand its TAM and reach sustainable profitability over time. I argue why CRSP is close to an inflection point, suggesting buyers should consider capitalizing on its recent pessimism. Read the full article on Seeking Alpha分析記事 • Jun 18
CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
You may think that with a price-to-sales (or "P/S") ratio of 19.3x CRISPR Therapeutics AG ( NASDAQ:CRSP ) is a stock to...Seeking Alpha • Jun 10
Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Summary CRISPR Therapeutics’ new gene-editing protocol gives it a legitimate claim to be the future of medicine. That powered the stock back in 2020-21. But at some point, it’ll take revenues and profits, not futurism to justify stock ownership. The in-progress launch of Casgevy, a gene-editing treatment for Sickle Cell Disease suggests that transition is closing in. But that’s still getting off the ground, making numbers hard to project, and leaving room for disappointments. Read the full article on Seeking AlphaSeeking Alpha • Jun 03
Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Summary CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the establishment of authorized treatment centers, and CRISPR has already set up more than 25 globally. Despite Q1 revenue missing estimates, the company is controlling expenses and shows a healthy balance sheet with a solid cash runway. The commercial success of Casgevy hinges on long-term patient outcomes and will likely face limited early adoption. Updated investment recommendation: change from "sell" to "hold" due to recent stock valuation adjustments and prudent expense management. Read the full article on Seeking Alpha分析記事 • May 23
Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
Key Insights CRISPR Therapeutics' Annual General Meeting to take place on 30th of May Total pay for CEO Sam Kulkarni...分析記事 • May 13
Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for CRISPR Therapeutics AG ( NASDAQ:CRSP ) shareholders, with the analysts delivering a...分析記事 • May 10
We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • May 09
Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
Summary Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales. Casgevy is approved to treat Sickle Cell Disease and Transfusion Dependent Beta Thalassemia in the U.S., EU, and other territories, with the potential to "functionally cure" patients. Crispr Therapeutics has a strong balance sheet, a diverse pipeline, and the potential to expand its reach to a larger patient population in the future. Its three targets ex-Casgevy are Type 1 diabetes, immuno-oncology, and in-vivo gene therapy - some compelling progress is being made in each field. In short - what's not to like? One day, Crispr Therapeutics will get the valuation upgrade it deserves. Read the full article on Seeking AlphaSeeking Alpha • May 03
Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
Summary Crispr Therapeutics AG stock has plunged deep into a bear market. The FOMO attributed to Crispr's Casgevy approvals is likely dissipated. Crispr has an expanding early-stage portfolio. Crispr is also gaining traction to improve Casgevy's safety profile. Crispr Therapeutics stock is also no longer overvalued, as late buyers likely rushed out quickly. The stock's selling intensify has also slowed, allowing dip-buyers an attractive opportunity to load up. Read the full article on Seeking AlphaSeeking Alpha • Apr 24
Crispr Therapeutics: Now Is The Time To Buy
Summary Despite recent FDA approvals for its groundbreaking gene editing technology, CRISPR Therapeutics' stock has experienced a decline in value. The company's pipeline of treatments for various diseases presents a significant opportunity for future growth and market expansion. CRISPR Therapeutics has managed financial risks through partnerships and has enough cash on hand to fund operations for at least 24 months. Read the full article on Seeking Alpha分析記事 • Apr 16
Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Key Insights The projected fair value for CRISPR Therapeutics is US$68.64 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Mar 26
Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Summary Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEVY in approved countries. Private insurers are showing interest in covering CASGEVY, providing further support for its commercial launch. Read the full article on Seeking Alpha分析記事 • Feb 22
There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
CRISPR Therapeutics AG ( NASDAQ:CRSP ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Feb 22
Crispr Therapeutics: Cautiously Optimistic
Summary CRISPR Therapeutics has experienced significant growth in the past five years, with its stock price soaring and then stabilizing around $80. The company has achieved regulatory approval for its CRISPR-based therapy for sickle cell disease and beta-thalassemia and has a diverse pipeline targeting various diseases. Investing in CRISPR Therapeutics requires risk tolerance and a long-term perspective, as the road to commercial success is complex and uncertain. Read the full article on Seeking AlphaSeeking Alpha • Feb 01
Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Summary Crispr Therapeutics recently received FDA approval for gene editing therapy, Casgevy for treating Sickle Cell Disease and Beta-Thalassemia. In this article I'll look at Casgevy's market potential and its commercialisation challenges. The cost of Casgevy, treatment cons, scalability and accessibility pose serious challenges for widespread adoption. Which may justify the high short interest in the stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 18
Crispr Therapeutics: Commercial Validation Is The Next Step
Summary CASGEVY is expecting more approvals from various global regulatory bodies, potentially increasing the total addressable patients. The management team is attempting to make CASGEVY more accessible through an in-vivo solution. The concerns surrounding commercial launch risks are overshadowed by the potential of CRISPR Therapeutics. Read the full article on Seeking AlphaSeeking Alpha • Jan 11
Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Summary CASGEVY is a groundbreaking gene therapy, owned by CRISPR AG and Vertex specifically designed for the treatment of sickle cell disease. Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as the first FDA-approved therapy utilizing CRISPR/Cas9. CASGEVY’s approach involves modifying the patient’s own hematopoietic (blood) stem cells using CRISPR/Cas9 technology. Read the full article on Seeking Alpha分析記事 • Dec 25
CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
You may think that with a price-to-sales (or "P/S") ratio of 29.7x CRISPR Therapeutics AG ( NASDAQ:CRSP ) is a stock to...分析記事 • Nov 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Oct 05
A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Key Insights Using the 2 Stage Free Cash Flow to Equity, CRISPR Therapeutics fair value estimate is US$44.37 Current...分析記事 • Sep 14
CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
With a price-to-sales (or "P/S") ratio of 23x CRISPR Therapeutics AG ( NASDAQ:CRSP ) may be sending very bearish...分析記事 • Jul 24
We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Jun 28
Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Key Insights CRISPR Therapeutics' estimated fair value is US$64.57 based on 2 Stage Free Cash Flow to Equity Current...分析記事 • Apr 02
CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Mar 06
CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, CRISPR Therapeutics fair value estimate is US$68.38 CRISPR...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 614 | -197 | -100 | 49 | 12 |
| 12/31/2027 | 150 | -389 | -273 | -213 | 20 |
| 12/31/2026 | 45 | -479 | -421 | -224 | 21 |
| 3/31/2026 | 4 | -569 | -426 | -400 | N/A |
| 12/31/2025 | 4 | -582 | -371 | -345 | N/A |
| 9/30/2025 | 38 | -488 | -328 | -302 | N/A |
| 6/30/2025 | 38 | -468 | -351 | -325 | N/A |
| 3/31/2025 | 38 | -386 | -308 | -306 | N/A |
| 12/31/2024 | 37 | -366 | -145 | -143 | N/A |
| 9/30/2024 | 203 | -240 | -191 | -189 | N/A |
| 6/30/2024 | 202 | -266 | -127 | -122 | N/A |
| 3/31/2024 | 272 | -217 | -169 | -159 | N/A |
| 12/31/2023 | 371 | -154 | -272 | -260 | N/A |
| 9/30/2023 | 170 | -354 | -295 | -278 | N/A |
| 6/30/2023 | 170 | -416 | -363 | -343 | N/A |
| 3/31/2023 | 100 | -524 | -377 | -352 | N/A |
| 12/31/2022 | 1 | -650 | -533 | -496 | N/A |
| 9/30/2022 | 14 | -681 | -509 | -468 | N/A |
| 6/30/2022 | 15 | -633 | -516 | -445 | N/A |
| 3/31/2022 | 915 | 312 | 414 | 504 | N/A |
| 12/31/2021 | 915 | 378 | 457 | 539 | N/A |
| 9/30/2021 | 902 | 412 | 465 | 544 | N/A |
| 6/30/2021 | 902 | 447 | 502 | 549 | N/A |
| 3/31/2021 | 1 | -392 | -309 | -287 | N/A |
| 12/31/2020 | 1 | -349 | -257 | -238 | N/A |
| 9/30/2020 | 77 | -211 | -167 | -154 | N/A |
| 6/30/2020 | 289 | 20 | 45 | 55 | N/A |
| 3/31/2020 | 289 | 46 | 40 | 48 | N/A |
| 12/31/2019 | 290 | 67 | N/A | 57 | N/A |
| 9/30/2019 | 213 | -11 | N/A | 25 | N/A |
| 6/30/2019 | 1 | -200 | N/A | -128 | N/A |
| 3/31/2019 | 2 | -185 | N/A | -117 | N/A |
| 12/31/2018 | 3 | -165 | N/A | -96 | N/A |
| 9/30/2018 | 35 | -117 | N/A | -83 | N/A |
| 6/30/2018 | 37 | -91 | N/A | -79 | N/A |
| 3/31/2018 | 40 | -75 | N/A | -69 | N/A |
| 12/31/2017 | 41 | -68 | N/A | -70 | N/A |
| 9/30/2017 | 11 | -51 | N/A | -75 | N/A |
| 6/30/2017 | 10 | -41 | N/A | -71 | N/A |
| 3/31/2017 | 7 | -36 | N/A | -69 | N/A |
| 12/31/2016 | 5 | -23 | N/A | -53 | N/A |
| 9/30/2016 | 3 | -53 | N/A | 33 | N/A |
| 6/30/2016 | 2 | -44 | N/A | 40 | N/A |
| 3/31/2016 | 1 | -31 | N/A | 51 | N/A |
| 12/31/2015 | 0 | -26 | N/A | 59 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: CRSP今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CRSP今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: CRSP今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: CRSPの収益 ( 64.1% ) US市場 ( 11.6% ) よりも速いペースで成長すると予測されています。
高い収益成長: CRSPの収益 ( 64.1% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: CRSP 3 年以内に赤字になると予測されています。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 11:02 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
CRISPR Therapeutics AG 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。40
| アナリスト | 機関 |
|---|---|
| Jack Allen | Baird |
| William Pickering | Bernstein |
| Alec Stranahan | BofA Global Research |